RIBO-THERAPEUTICS LLC

Carlsbad, CA · Biotech · Private

QuickRibo-mRNA method for rapid ribosome profiling and translatome identification

Grants
$655K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A quick and simplified method (QuickRibo-mRNA) for isolation of ribosome protected mRNA fragments for translatome identification$301,818
Federal grantDepartment of Health and Human Services · Phase I · A quick, and robust, and unbiased platform for circular RNAs isolation, discovery and profiling.$352,929
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1605THERALINK TECHNOLOGIES, INC.—$2.6M
1606Reglagene, LLC—$1.9M
1607XenoTherapeutics Corp—$1.3M
1608RIBO-THERAPEUTICS LLC——
1609Yuva Biosciences, Inc.—$1.1M
1610CEL-SCI CORPORATION—$1.1M
1611CELL ORIGINS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.